BS-002

BS-002 (also known as BS HH 002.SA) is a small molecule protein synthesis inhibitor being developed by Shanghai Bensen Pharmaceutical for the treatment of myeloid malignancies, including relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The drug is a subcutaneous formulation of homoharringtonine (also known as omacetaxine mepesuccinate), a plant alkaloid that interferes with the elongation step of protein translation. By binding to the A-site of the 60S ribosomal subunit, BS-002 prevents the correct positioning of aminoacyl-tRNA, leading to the rapid depletion of short-lived proteins essential for leukemic cell survival, such as the anti-apoptotic protein Mcl-1. The subcutaneous delivery route is intended to offer improved patient convenience and potentially a more favorable pharmacokinetic profile compared to traditional intravenous infusions of the same active ingredient.

Other names

subcutaneous homoharringtoninesubcutaneous omacetaxine mepesuccinate